ストックスクリーナーアプリを入手
57.59
2.06%
1.1454
前日終値:
$56.44
開ける：
$56.65
24時間の取引高:
3.78M
Relative Volume:
0.34
時価総額：
$117.60B
収益：
$48.48B
当期純損益:
$7.27B
株価収益率:
16.16
EPS:
3.5626
ネットキャッシュフロー:
$11.91B
1週間 パフォーマンス:
+4.00%
1か月 パフォーマンス:
+5.77%
6か月 パフォーマンス:
+7.75%
1年 パフォーマンス:
+20.94%
1日の値動き範囲:
$56.41
$57.82
1週間の範囲:
$55.40
$58.88
52週間の値動き範囲:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.59 | 117.66B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,210.83 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.08 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
259.75 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.60 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.16 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | アップグレード | UBS | Neutral → Buy |
| 2025-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-12-12 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 開始されました | Piper Sandler | Overweight |
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Insider Monkey
Bristol Myers Squibb (BMY) Joins Defensive Value Indexes, Is It Still 8% Undervalued? - simplywall.st
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Hires Lobbyist on Drug Pricing - Legis1
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Investigations Launched into Bristol Myers Squibb (BMY) and Othe - GuruFocus
Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha
Beeline ups its Series A round for immune drug work - BioPharma Dive
Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates? - Insider Monkey
Bristol Myers Squibb adjusts its growth profile as FTSE Russell reshapes indexes. Dividend and earni - AD HOC NEWS
Exclusive: House China panel questions Bristol Myers, Pfizer and others on trial sites - Endpoints News
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb updates strategy for Zeposia, shares react to pipeline focus - AD HOC NEWS
Bristol Myers Squibb adjusts expectations on key cancer drug, shares react to analyst debate - AD HOC NEWS
Chemung Canal Trust Co. Increases Position in Bristol Myers Squibb Company $BMY - MarketBeat
Camzyos from Bristol-Myers Squibb Co.targeted heart failure therapy reshapes daily routines - Ad-hoc-news.de
The Opdivo from Bristol-Myers Squibb Co.PD-1 blocker reshapes melanoma therapy - Ad-hoc-news.de
Bristol-Myers Squibb Co (BMY) Stock Up 3.9% but GF Value Says Ov - GuruFocus
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
OmniStar Financial Group, Inc.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Play with Cautionary Notes - ChartMill
Bristol-Myers Squibb focuses on analyst expectations, shares in S&P 500 spotlight - Ad-hoc-news.de
Bristol Myers Squibb clears key cancer drug hurdle, shares in focus after FDA panel backing - Ad-hoc-news.de
BMYBristol-Myers Squibb Co Volatility & Greeks - Finviz
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb -- Barrons.com - Moomoo
Bristol Myers Follows Novartis, Sues Arkansas Over Pharmacy Law - Bloomberg Law News
Bristol Myers Squibb sets next earnings date, shares trade steadily on NYSE - Ad-hoc-news.de
Opdivo from Bristol-Myers Squibb Co.immunotherapy mainstay with new combo data - Ad-hoc-news.de
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies - Insider Monkey
Bristol Myers Squibb weighs dividend reset, shares trade near recent lows - AD HOC NEWS
3 Reasons to Buy Bristol Myers Squibb Stock - The Motley Fool
Bristol-Myers Squibb Company (BMY) Stock Analysis: Exploring the 16.81% Upside Potential for Investors - DirectorsTalk Interviews
Bristol-Myers Squibb Co (BMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bristol-Myers Squibb Co (CELG_r) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now - Kavout | AI
Bristol-Myers Squibb StockLong-term pipeline and business model under review - AD HOC NEWS
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb Co (CELG_r) Institutional Confidence - TradingKey
Bristol-Myers Squibb Co (CELG_r) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Valuation: PE, PB & Fair Value Analysis - TradingKey
CHEMUNG CANAL TRUST CO's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bristol-Myers Squibb Company: Target Price Consensus and Analysts Recommendations | BMY | US1101221083 - marketscreener.com
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend at $0.63 per Share - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Faithward Advisors, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes - Yahoo Finance
Measured Wealth Private Client Group, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (BMY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
大文字化:
|
ボリューム (24 時間):